nach oben

High Blood Pressure & Cardiovascular Prevention

Erschienen in:

01.09.2022 | Original article

Cardiovascular Risk Stratification and Appropriate Use of Statins in Patients with Chronic Kidney Disease According to Different Strategies

verfasst von: Leandro Barbagelata, Walter Masson, Emiliano Rossi, Martin Lee, Juan Lagoria, Manuel Vilas, Rodolfo Pizarro, Guillermo Rosa Diez

Erschienen in: High Blood Pressure & Cardiovascular Prevention | Ausgabe 5/2022

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Different strategies were proposed to stratify cardiovascular risk and assess the appropriate use of statins in patients with chronic kidney disease (CKD).

Aim

(1) To apply two strategies on the management of lipids in patients with CKD, analyzing what proportion of patients received lipid-lowering treatment and how many patients without statin therapy would be candidates for receiving them; (2) to identify how many patients achieve the lipid goals.

Methods

A cross-sectional study was performed. Patients aged between 18 to 70 years and CKD with an estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73 m² (without hemodialysis) were included. The indications for statin therapy according to 2019 ESC/EAS and 2013 KDIGO guidelines were analyzed as well as the achievement of LDL-C goals.

Results

A total of 300 patients were included. According to ESC/EAS guidelines, 62.3 and 37.7% of the population was classified at high or very high cardiovascular risk. In total, 52% of patients received statins. Applying the 2013 KDIGO and the 2019 ESC/EAS guidelines, 92.4 and 95.8% of the population without lipid-lowering treatment were eligible for statin therapy, respectively. Globally, only 9.1 and 10.6% of the patients with high or very high risk achieved the suggested lipid goals.

Conclusion

A large proportion of patients with CKD showed considerable cardiovascular risk and were eligible for statin therapy according to the two strategies evaluated. However, observed statin use was deficient and current lipid goals were not achieved in most cases.

Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296–305. https://doi.org/10.1056/NEJMoa041031.CrossRefPubMed

Shroff GR, Carlson MD, Mathew RO. Coronary artery disease in chronic kidney disease: need for a heart-kidney team-based approach. Eur Cardiol. 2021;7(16): e48. https://doi.org/10.15420/ecr.2021.30.CrossRef

Theofilis P, Vordoni A, Koukoulaki M, Vlachopanos G, Kalaitzidis RG. Dyslipidemia in chronic kidney disease: contemporary concepts and future therapeutic perspectives. Am J Nephrol. 2021;52(9):693–701. https://doi.org/10.1159/000518456.CrossRefPubMed

Hamrahian SM, Falkner B. Hypertension in chronic kidney disease. Adv Exp Med Biol. 2017;956:307–25. https://doi.org/10.1007/5584_2016_84.CrossRefPubMed

Takx RAP, MacNabb MH, Emami H, Abdelbaky A, Singh P, Lavender ZR, di Carli M, Taqueti V, Foster C, Mann J, Comley RA, Weber CI, Tawakol A. Increased arterial inflammation in individuals with stage 3 chronic kidney disease. Eur J Nucl Med Mol Imaging. 2016;43:333–9. https://doi.org/10.1007/s00259-015-3203-6.CrossRefPubMed

Fakhry M, Sidhu MS, Bangalore S, Mathew RO. Accelerated and intensified calcific atherosclerosis and microvascular dysfunction in patients with chronic kidney disease. Rev Cardiovasc Med. 2020;21(2):157–62. https://doi.org/10.31083/j.rcm.2020.02.99.CrossRefPubMed

Mok Y, Ballew SH, Matsushita K. Chronic kidney disease measures for cardiovascular risk prediction. Atherosclerosis. 2021;335:110–8. https://doi.org/10.1016/j.atherosclerosis.2021.09.007.CrossRefPubMed

Hager MR, Narla AD, Tannock LR. Dyslipidemia in patients with chronic kidney disease. Rev Endocr Metab Disord. 2017;18(1):29–40. https://doi.org/10.1007/s11154-016-9402-z.CrossRefPubMed

Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen MR, Tokgozoglu L, Wiklund O, ESC Scientific Document Group. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–88. https://doi.org/10.1093/eurheartj/ehz455.CrossRefPubMed

10.

Wanner C, Tonelli M. KDIGO clinical practice guideline for lipid management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney Int. 2014;85(6):1303–9. https://doi.org/10.1038/ki.2014.31.CrossRefPubMed

11.

Levey AS, Stevens LA. Estimating GFR using the CKD Epidemiology Collaboration (CKD-EPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions. Am J Kidney Dis. 2010;55(4):622–7. https://doi.org/10.1053/j.ajkd.2010.02.337.CrossRefPubMedPubMedCentral

12.

Douville P, Martel AR, Talbot J, Desmeules S, Langlois S, Agharazii M. Impact of age on glomerular filtration estimates. Nephrol Dial Transplant. 2009;24(1):97–103. https://doi.org/10.1093/ndt/gfn473.CrossRefPubMed

13.

Wilson PW, D’Ágostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease sing risk factor categories. Circulation. 1998;97(18):1837–47. https://doi.org/10.1161/01.cir.97.18.1837.CrossRefPubMed

14.

McCullough PA, Jurkovitz CT, Pergola PE, McGill JB, Brown WW, Collins AJ, Chen SC, Li S, Singh A, Norris KC, Klag MJ, Bakris GL, KEEP Investigators. Independent components of chronic kidney disease as a cardiovascular risk state: results from the Kidney Early Evaluation Program (KEEP). Arch Intern Med. 2007;167(11):1122–9. https://doi.org/10.1001/archinte.167.11.1122.CrossRefPubMed

15.

McCullough PA, Verrill TA. Cardiorenal interaction: appropriate treatment of cardiovascular risk factors to improve outcomes in chronic kidney disease. Postgrad Med. 2010;122(2):25–34. https://doi.org/10.3810/pgm.2010.03.2119.CrossRefPubMed

16.

Matsushita K, Coresh J, Sang Y, Chalmers J, Fox C, Guallar E, Jafar T, Jassal SK, Landman GWD, Muntner P, Roderick P, Sairenchi T, Schöttker B, Shankar A, Shlipak M, Tonelli M, Townend J, Zuilen AV, Yamagishi K, Yamashita K, Gansevoort R, Sarnak M, Warnock DG, Woodward M, Ärnlöv J, CKD Prognosis Consortium. Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data. Lancet Diabetes Endocrinol. 2015;3(7):514–25. https://doi.org/10.1016/S2213-8587(15)00040-6.CrossRefPubMedPubMedCentral

17.

Cholesterol Treatment Trialists’ (CTT) Collaboration, Fulcher J, O’Connell R, Voysey M, Emberson J, Blackwell L, Mihaylova B, Simes J, Collins R, Kirby A, Colhoun H, Braunwald E, La Rosa J, Pedersen TR, Tonkin A, Davis B, Sleight P, Franzosi MG, Baigent C, Keech A. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015;385(9976):1397–405. https://doi.org/10.1016/S0140-6736(14)61368-4.CrossRef

18.

Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–81. https://doi.org/10.1016/S0140-6736(10)61350-5.CrossRef

19.

Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, Wanner C, Krane V, Cass A, Craig J, Neal B, Jiang L, Hooi LS, Levin A, Agodoa L, Gaziano M, Kasiske B, Walker R, Massy A, Feldt-Rasmussen B, Krairittichai U, Ophascharoensuk V, Fellström B, Holdaas H, Tesar V, Wiecek A, Grobbee D, de Zeeuw D, Grönhagen-Riska C, Dasgupta T, Lewis D, Herrington W, Mafham M, Majoni W, Wallendszus K, Grimm R, Pedersen T, Tobert J, Armitage J, Baxter A, Bray C, Chen Y, Chen Z, Hill M, Knott C, Parish S, Simpson D, Sleight P, Young A, Collins R, SHARP Investigators. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomized placebo-controlled trial. Lancet. 2011;377(9784):2181–92. https://doi.org/10.1016/S0140-6736(11)60739-3.CrossRefPubMedPubMedCentral

20.

Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Perkovi V, Hegbrant J, Strippoli JFM. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev. 2014;(5):CD007784. https://doi.org/10.1002/14651858.CD007784.pub2.

21.

Wanner C, Krane V, März W, Olschewski M, Mann JFE, Ruf G, Ritz E, German Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353(3):238–48. https://doi.org/10.1056/NEJMoa043545.CrossRefPubMed

22.

Fellström BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, Chae DW, Chevaile A, Cobbe SM, Grönhagen-Riska C, De Lima JJ, Lins R, Mayer G, McMahon AW, Parving HH, Remuzzi G, Samuelsson O, Sonkodi S, Sci D, Süleymanlar G, Tsakiris D, Tesar D, Todorov V, Wiecek A, Wüthrich RP, Gottlow M, Johnsson E, Zannad F, AURORA Study Group. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360(14):1395–407. https://doi.org/10.1056/NEJMoa0810177.CrossRefPubMed

23.

Vega GL, Wang J, Grundy SM. Chronic kidney disease and statin eligibility. J Clin Lipidol. 2021;15(1):173–80. https://doi.org/10.1016/j.jacl.2020.10.004.CrossRefPubMed

24.

Markossian TW, Kramer HJ, Burge NJ, Pacold IV, Leehey DJ, Huo Z, Schneider J, Ling B, Stroupe KT. Low statin use in nondialysis-dependent chronic kidney disease in the absence of clinical atherosclerotic cardiovascular disease or diabetes. Clin Kidney J. 2019;12(4):530–7. https://doi.org/10.1093/ckj/sfy131.CrossRefPubMedPubMedCentral

25.

Galán I, Verdalles U, García de Vinuesa M, Quiroga B, Goicoechea M, Pérez A, Verde E, Luño J. Impact of the application of the JNC 8 and KDIGO-2013 guidelines on hypertension and lipid control in a Nephrology outpatient clinic. Nefrologia (Engl Ed). 2018;38(4):379–85. https://doi.org/10.1016/j.nefro.2017.10.003.CrossRefPubMed

26.

Feinstein AR, Cicchetti DV. High agreement but low kappa: I. The problems of two paradoxes. J Clin Epidemiol. 1990;43(6):543–9. https://doi.org/10.1016/0895-4356(90)90158-l.CrossRefPubMed

27.

Gulayin P, Lozada A, Beratarrechea A, et al. An educational intervention to improve statin use: cluster RCT at the primary care level in Argentina. Am J Prev Med. 2019;57(1):95–105. https://doi.org/10.1016/j.amepre.2019.02.018 (Epub 2019 May 23).CrossRefPubMed

28.

Kim LG, Cleary F, Wheeler DC, Caplin B, Nitsch D, Hull SA, UK National Chronic Kidney Disease Audit. How do primary care doctors in England and Wales code and manage people with chronic kidney disease? Results from the National Chronic Kidney Disease Audit. Nephrol Dial Transplant. 2018;33(8):1373–9. https://doi.org/10.1093/ndt/gfx280.CrossRefPubMed

29.

Massy ZA, Ferrières J, Bruckert E, Lange C, Liabeuf S, Velkovski-Rouyer M, Stengel B. Achievement of low-density lipoprotein cholesterol targets in CKD. Kidney Int Rep. 2019;4(11):1546–54. https://doi.org/10.1016/j.ekir.2019.07.014 (eCollection 2019 Nov).CrossRefPubMedPubMedCentral

30.

Schneider MP, Hübner S, Titze SI, Schmid M, Nadal J, Schlieper G, Busch M, Baid-Agrawal S, Krane V, Wanner C, Kronenberg F, Eckardt KU. Implementation of the KDIGO guideline on lipid management requires a substantial increase in statin prescription rates. Kidney Int. 2015;88(6):1411–8. https://doi.org/10.1038/ki.2015.246 (Epub 2015 Sep 2).CrossRefPubMed

31.

Monaldi B, Bologna G, Costa GG, D’Agostino C, Ferrante F, Filice M, Grion AM, Mingarelli A, Paloscia L, Tettamanti R, Veronesi C, Esposti LD. Adherence to statin treatment following a myocardial infarction: an Italian population-based survey. Clinicoecon Outcomes Res. 2015;7:273–80. https://doi.org/10.2147/CEOR.S70936 (eCollection 2015).CrossRefPubMedPubMedCentral

32.

De Backer G, Jankowski P, Kotseva K, Mirrakhimov E, Reiner Z, Rydén L, Tokgözoğlu L, Wood D, De Bacquer D, EUROASPIRE V collaborators. Management of dyslipidemia in patients with coronary heart disease: results from the ESC-EORP EUROASPIRE V survey in 27 countries. Atherosclerosis. 2019;285:135–46. https://doi.org/10.1016/j.atherosclerosis.2019.03.014.CrossRefPubMed

33.

Gencer B, Marston NA, Im K, Cannon CP, Sever P, Keech A, Braunwald E, Giugliano RP, Sabatine MS. Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials. Lancet. 2020;396(10263):1637–43. https://doi.org/10.1016/S0140-6736(20)32332-1.CrossRefPubMedPubMedCentral

34.

Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, Benetos A, Biffi A, Boavida JM, Capodanno D, Cosyns B, Crawford C, Davos CH, Desormais L, Di Angelantonio E, Franco OH, Halvorsen, Hobbs FDR, Hollander M, Jankowska EA, Michal M, Sacco S, Sattar N, Tokgozoglu L, Tonstad S, Tsioufis KP, Van Dis I, Van Gelder IC, Wanner C, Williams B, ESC Scientific Document Group. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur J Prev Cardiol. 2022;29(1):5–115. https://doi.org/10.1093/eurjpc/zwab154.CrossRefPubMed

35.

Rangaswami J, Mathew RO, McCullough PA. Resuscitation for the specialty of nephrology: is cardionephrology the answer? Kidney Int. 2018;93(1):25–6. https://doi.org/10.1016/j.kint.2017.10.002.CrossRefPubMed

Titel: Cardiovascular Risk Stratification and Appropriate Use of Statins in Patients with Chronic Kidney Disease According to Different Strategies
verfasst von: Leandro Barbagelata
Walter Masson
Emiliano Rossi
Martin Lee
Juan Lagoria
Manuel Vilas
Rodolfo Pizarro
Guillermo Rosa Diez
Publikationsdatum: 01.09.2022
Verlag: Springer International Publishing
Erschienen in: High Blood Pressure & Cardiovascular Prevention / Ausgabe 5/2022
Print ISSN: 1120-9879
Elektronische ISSN: 1179-1985
DOI: https://doi.org/10.1007/s40292-022-00531-8

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Cardiovascular Risk Stratification and Appropriate Use of Statins in Patients with Chronic Kidney Disease According to Different Strategies

Abstract

Introduction

Aim

Methods

Results

Conclusion

Neu im Fachgebiet Kardiologie

Ist Fasten vor Koronarinterventionen wirklich nötig?

PET kann infarktgefährdete Koronararterien entdecken

GLP-1-Agonist Semaglutid wirkt kardio- und nephroprotektiv

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

Update Kardiologie

Springer Medizin

Abstract

Introduction

Aim

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2022

Flu Vaccination as a Key Prevention Recommendation for Patients at High Cardiovascular Risk: The Next Season’s Scenario

Acupuncture in Arterial Hypertension: Evaluation of its Efficacy with Both Office and Ambulatory Blood Pressure Measurements

Use of an Automated Discharge Instruction Module to Improve Outpatient Follow-Up for Emergency Department Patients with Elevated Blood Pressure

Developing and Validating Risk Algorithm for Hypertension in South Africa: Results from a Nationally Representative Cohort (2008–2017)

The Influence of ABCB1 (rs1045642 and rs4148738) Gene Polymorphisms on Rivaroxaban Pharmacokinetics in Patients Aged 80 Years and Older with Nonvalvular Atrial Fibrillation

2022 NATIONAL CONGRESS OF THE ITALIAN SOCIETY OF HYPERTENSION (SIIA)

Neu im Fachgebiet Kardiologie

Ist Fasten vor Koronarinterventionen wirklich nötig?

PET kann infarktgefährdete Koronararterien entdecken

GLP-1-Agonist Semaglutid wirkt kardio- und nephroprotektiv

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

Update Kardiologie